98%
921
2 minutes
20
Background: A new voltage-gated Ca channel αδ ligand, mirogabalin, was first approved for treating peripheral neuropathic pain in Japan in 2019. This is the first report on the prescription status of mirogabalin using a large-scale prescription database.
Research Design And Methods: The authors analyzed the prescription data of 12,924 patients prescribed mirogabalin between 1 June and 31 August 2020. The endpoints were the number of patients prescribed, prescription days, prescription doses, dose changes, co-prescription patterns, medication possession ratio (MPR), and treatment discontinuation rates (TDRs).
Results: Mirogabalin was newly prescribed to 7,914 patients in the 3-month study period. Most patients were prescribed mirogabalin at about 10 mg/day during the study period, and 30.9% of patients were prescribed ≥ 20 mg/day on Day 90 after the first prescription. The most frequently prescribed concomitant drug was celecoxib. The MPR (80 to 110%) was 86.2%, indicating good treatment adherence. The cumulative TDRs during ≤ 7 Days, Days 31-60, and 61-90 were 14.0%, 70.0%, and 77.9%, respectively.
Conclusions: Mirogabalin was prescribed to a considerable number of patients. These results may be useful for optimizing mirogabalin use for patients with peripheral neuropathic pain in daily clinical practice.
Clinical Trial Registration Number: UMIN000042592.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/14656566.2021.2007239 | DOI Listing |
Retin Cases Brief Rep
September 2025
Doheny Eye Institute, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
Purpose: To report the examination and multimodal imaging findings of a patient with unilateral bull's eye maculopathy.
Methods: A retrospective chart review of a 77-year-old patient with unilateral bull's eye maculopathy who presented to a tertiary retinal practice was performed. The patient's history, visual acuity, examination and multimodal imaging findings over five years of follow-up were described.
PLoS One
September 2025
Department of Social Medicine and Health Management, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Background: Antimicrobial resistance is a globally recognised public health threat. In rural China, antibiotic use is common for acute respiratory infections (ARIs), which include symptoms such as coughing and fever that are most likely viral infections but with a small proportion as bacterial infections. This study aims to evaluate the effectiveness of a comprehensive intervention based on C-reactive protein and serum amyloid A point-of-care testing (CRP&SAA POCT) in reducing the inappropriate use of antibiotics for ARIs in Chinese village clinics.
View Article and Find Full Text PDFPLoS One
September 2025
Chilean Invasive Mycosis Network, Santiago, Chile.
Background: Invasive mold diseases (IMDs) are a severe complication of immunocompromised subjects and an emerging problem among severely ill, apparently immunocompetent patients. The aim of this study was to describe the epidemiological and clinical features of IMDs in Chile.
Methods: Prospective study of IMD cases in children and adults from 11 reference hospitals in Chile from May 2019 to May 2021.
J Infect Dev Ctries
August 2025
Division of Epidemiology and Biostatistics, Global Health Department, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Introduction: Severe bacterial infections cause significant disease burden in developing countries, including Malawi. The situation is compounded by the scarcity of resources, inconsistent availability of antibiotics, and increasing antimicrobial resistance (AMR).
Methodology: This was a descriptive retrospective study where we analyzed blood culture results of pediatric patients admitted to Kamuzu Central Hospital (KCH), Lilongwe, Malawi.
Interv Neuroradiol
September 2025
Department of Neuroradiology, Walton Centre for Neurology and Neurosurgery, Liverpool, UK.
ObjectiveThis study aims to determine the outcomes of nickel allergic patients who underwent a trial of forearm arterial stenting with a nickel-based stent, with follow-up to assess for an allergic reaction. In the absence of adverse effects, patients had their intracranial aneurysm treatment with a nickel-based cerebrovascular device.MethodsA retrospective analysis was performed on patients who had an allergy to nickel, with an intracranial aneurysm who underwent treatment with a permanently implanted nickel-containing device.
View Article and Find Full Text PDF